Emerging biotech companies must navigate the complexities of development and approval – often with no previous experience. Speed, quality, predictability, and risk management are a few of the many reasons biotech sponsors need one partner for all study reviews.
Download our whitepaper to:
- Determine the need for an IBC.
- Assess prospective site lists.
- Ascertain the need for EACs and DMCs.
- Understand independent reviews.
- Discover how one partner for IRB, IBC, EAC, DMC saves resources.